clinical trial · NCT07197866
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
Teva Branded Pharmaceutical Products R&D LLC·phase2·recruiting·n = 200
Multiple System AtrophyTEV-56286
brief summary
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.
started
Sep 30, 2025
primary completion
May 3, 2029
completion
May 17, 2029
last updated
Jun 10, 2026
official title
An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol